Literature DB >> 9020900

Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes.

G Ribéreau-Gayon1, S Dumont, C Muller, M L Jung, P Poindron, R Anton.   

Abstract

The three mistletoe (Viscum album L.) lectins. ML I, ML II and ML III, were tested on their ability to enhance the secretion of the cytokines tumor necrosis factor (TNF)alpha, interleukin (IL)-1 alpha, IL-1 beta and IL-6 by human monocytes obtained from healthy donors. At lectin concentrations from 0.02 to 20/pg ml (100-10,000-fold lower than those showing toxic effects), stimulations of cytokine production several-fold over control values were observed. The immunoactivating concentrations by the three lectins were found different for each donor. At toxic concentrations, the amounts of IL-1 alpha, IL-1 beta and to a less extent of TNF alpha in monocytes supernatants were particularly high. The data are discussed in relationship with the cytotoxic and immunoactivating effects of mistletoe lectins and their interest in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9020900     DOI: 10.1016/s0304-3835(96)04401-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro.

Authors:  U Elsässer-Beile; M Voss; R Schühle; U Wetterauer
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Anti-inflammatory effect of Viscum album agglutinin-I (VAA-I): induction of apoptosis in activated neutrophils and inhibition of lipopolysaccharide-induced neutrophilic inflammation in vivo.

Authors:  V Lavastre; H Cavalli; C Ratthe; D Girard
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

3.  Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo.

Authors:  Lucie Heinzerling; Volker von Baehr; Christa Liebenthal; Rüdiger von Baehr; Hans-Dieter Volk
Journal:  J Clin Immunol       Date:  2006-05-17       Impact factor: 8.317

4.  Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses.

Authors:  Yan-Hui Ma; Wei-Zhi Cheng; Fang Gong; An-Lun Ma; Qi-Wen Yu; Ji-Ying Zhang; Chao-Ying Hu; Xue-Hua Chen; Dong-Qing Zhang
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

Review 5.  Mistletoe therapy in oncology.

Authors:  M A Horneber; G Bueschel; R Huber; K Linde; M Rostock
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

6.  Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.

Authors:  Soo Jung Lee; Young-Ok Son; Hyunjin Kim; Joo-Young Kim; Soon-Won Park; Jae-Ho Bae; Hyung Hoi Kim; Eun-Yup Lee; Byung-Seon Chung; Sun-Hee Kim; Chi-Dug Kang
Journal:  J Clin Immunol       Date:  2007-05-25       Impact factor: 8.317

7.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

8.  Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells.

Authors:  Katharina Mulsow; Thomas Enzlein; Catharina Delebinski; Sebastian Jaeger; Georg Seifert; Matthias F Melzig
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

9.  Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice.

Authors:  Te-Sheng Lien; Der-Shan Sun; Cheng-Yeu Wu; Hsin-Hou Chang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

10.  NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.

Authors:  Patrick J Mansky; Dawn B Wallerstedt; Timothy S Sannes; Jamie Stagl; Laura Lee Johnson; Marc R Blackman; Jean L Grem; Sandra M Swain; Brian P Monahan
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.